Legal tactics to delay launch of generic drugs cost Europe €3bn, report says

BMJ 2008; 337 doi: (Published 01 December 2008) Cite this as: BMJ 2008;337:a2817
  1. Andrew Jack
  1. 1Financial Times

    Drug companies are bracing themselves for the launch of a series of antitrust investigations in Europe after the European Commission published a highly critical report on industry practices.

    The 426 page preliminary report by the commission’s Competition Directorate, which is to be followed by a final version next spring, highlights widespread legal tactics by drug companies to defend their patents. The commission says that such tactics have delayed the entry of cheaper generic drugs, at a cost of €3bn (£2.5bn; $3.8bn) since the start of the decade.

    It cites instances of companies starting litigation to hold up competing products, filing multiple patent …

    View Full Text

    Sign in

    Log in through your institution